LIFECORE BIOMEDICAL, INC. \DE\
LFCR · XNASCIK 1005286fmd_0JJ681DWPMQP2KWJX66EVG23B6Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jun 01, 2009 to Sep 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 477 | 470 | 524 | 558 | 160 | 101 | 111 | 103 | 128 | 129 |
| Cost of revenue | 410 | 391 | 446 | 477 | 121 | 62 | 72 | 75 | 86 | 89 |
| Gross profit | 67 | 79 | 78 | 81 | 39 | 39 | 39 | 28 | 42 | 40 |
| Provision for credit losses | – | – | – | – | – | 1 | (0) | 0 | 0 | – |
| Research and development | 7 | 9 | 13 | 11 | 8 | 7 | 8 | 9 | 9 | 8 |
| Selling, general and administrative | 46 | 52 | 52 | 62 | 41 | 28 | 35 | 39 | 40 | 44 |
| Total operating expenses | 87 | 65 | 65 | 76 | 65 | 48 | 51 | 50 | 51 | – |
| Operating income | (21) | 15 | 14 | 5 | (26) | (9) | (12) | (22) | (9) | (17) |
| Interest expense | 2 | – | – | – | 5 | 9 | 16 | 18 | 18 | 22 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 1 | 1 | 3 | 2 | (0) | (11) | 1 | (1) | (3) | (0) |
| Income before taxes | (20) | 14 | 16 | 4 | (31) | (30) | (21) | (64) | 10 | (39) |
| Income tax expense | (8) | 4 | (9) | 2 | (9) | (6) | (5) | 0 | 0 | 0 |
| Net income from continuing operations | (12) | 10 | 26 | 2 | (22) | (23) | (15) | (64) | 9 | (39) |
| Net income | (12) | 11 | 25 | 0 | (38) | (32) | (117) | (100) | 12 | (39) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | 12 | (44) |